Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Jasper Therapeutics Inc.
Headquarters: Redwood City, CA, United States of America
Website: http://www.jaspertherapeuti...
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Ronald A. Martell
Number Of Employees: 64
Enterprise Value: $242,000,521
PE Ratio: -0.87
Exchange/Ticker 1: NASDAQ:JSPR
Exchange/Ticker 2: N/A
Latest Market Cap: $63,543,500
BioCentury | Jan 22, 2025
Product Development
Vir, Sana gain new modality POC: BioCentury’s Clinical Report
Plus readouts from Jasper, Dyne and more
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Oct 15, 2024
Product Development
MeiraGTx data bring early POC for Parkinson’s gene therapy and localized gene expression strategy
In BioCentury’s latest Clinical Report, Skysona’s cancer risk comes into focus, GSK’s IL-5 meets in rhinosinusitis, Jasper’s c-Kit improves hives, and more
BioCentury | Feb 10, 2024
Finance
Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons
Plus PIPEs for Adverum, Autolus, Mineralys, Silence, PepGen, Sensorion, Tenaya, Jasper and others
BioCentury | Jan 18, 2024
Finance
VC roundup: Tr1X, Disco among the week’s launches
Plus: Comanche, Ratio, Advanced Medicine Partners and others raise cash
BioCentury | Nov 2, 2023
Management Tracks
Sam Raha named COO at Myriad
Plus: Endeavor hires a new CMO, and updates from Jasper, Syantra, Ocuphire, Senisca and more
BioCentury | Jun 13, 2023
Management Tracks
Patni becomes chief of R&D at Reata
Plus: Reilly named CEO at Damona, and updates from Akebia, Generate, Jasper and more
BioCentury | Apr 14, 2023
Management Tracks
Editas names Reeve chair, adds Levy to board
Plus: Exelixis proposes new directors amid ongoing tussle with activist investor and updates from Jasper, CIRM, Visus, Curemark and more
BioCentury | Mar 23, 2023
Management Tracks
Treco to succeed Bolte as CEO of Inozyme
Plus: Seagen’s Siegall to be CEO at Morphimmune and updates from Jasper, Vividion and more
BioCentury | Jan 26, 2023
Finance
Jan. 25 Finance Quick Takes: Pliant leads follow-on pack
Plus: Dimension launches with $350M fund for start-ups, and updates from Atomic AI
Items per page:
1 - 10 of 18